Caris Life Sciences to Present New Data at ESMO 2021 Highlighting Gene Expression in Colorectal Cancer - Comprehensive Profiling and Clinical Value apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
email article
Single-agent immune checkpoint inhibition after surgery reduced the risk of disease recurrence or death in patients with high-risk clear cell renal cell carcinoma (RCC), findings from a phase III study showed.
The KEYNOTE-564 trial met its primary endpoint, demonstrating that adjuvant pembrolizumab (Keytruda) following nephrectomy significantly increased disease-free survival (DFS) versus placebo (HR 0.68, 95% CI 0.53-0.87,
P=0.001), reported Toni Choueiri, MD, of the Dana-Farber Cancer Institute in Boston.
At 1 and 2 years, respectively, DFS rates were 85.7% and 77.3% with the PD-1 inhibitor, as compared with 76.2% and 68.1% with placebo, a clinically meaningful improvement, Choueiri said at a press briefing ahead of the virtual American Society of Clinical Oncology (ASCO) annual meeting.
email article
A healthy 46-year-old woman presents to the hospital in Dammam, Saudi Arabia for investigation of an incidental localized right renal mass, discovered in the course of an examination for gallstones. The mass is clinical stage I. Clinicians note that the patient has good performance status, and she reports no active concerns.
Findings from their initial assessment are unremarkable a systemic review is normal and the patient reports having no family history of kidney problems or renal cancers. Clinicians physical examination reveals nothing unusual, and results of lab tests are normal.
Clinicians perform a right radical nephrectomy, and pathologic analysis of the mass identifies clear cell renal cell carcinoma (ccRCC).